Catalent to work with Samsung Bioepis on biosim production

Global CMO Catalent will help Samsung Bioepis supply its Enbrel biosimilar in Europe, where it is marketed by Biogen. 

By Suzanne Elvidge • Oct. 20, 2016

Moderna taps Catalent for clinical manufacturing

The well-funded Cambridge biotech has been busy expanding its manufacturing capacity as it ramps up clinical development of several mRNA programs. 

By Jacob Bell • Oct. 17, 2016

Bluebird touts upgrades to gene therapy

A new manufacturing process could boost the effectiveness of its Lentiglobin product. Investors seem to want more.

By Ned Pagliarulo • Oct. 16, 2016

Are pharmaceutical supply chains ill-regulated?

Regulators have been clamping down on Indian and Chinese drugmakers in an effort to raise the countries' compliance with good manufacturing practices.

By Edwin Lopez , Jennifer McKevitt • Oct. 13, 2016

Chinese drugmaker, 3 others warned in FDA letters

The China-based company was missing an active ingredient in at least one batch of drug product.

By Jacob Bell • Oct. 13, 2016

Biotrial opens North American HQ, has successful audit

Although still reeling from a deadly drug trial in January, Biotrial of France is moving forward, opening its North American headquarters in New Jersey. 

By Joe Cantlupe • Oct. 13, 2016

AstraZeneca snaps up Amgen site in Colorado

The newly acquired facility will support another Colorado plant AstraZeneca bought from Amgen last year, both of which are focused on biologics. 

By Suzanne Elvidge • Oct. 13, 2016

Catalent out-licenses ADC to Triphase

Triphase Accelerator of San Diego purchased rights to Catalent’s anti-body drug conjugate platform to make clinical headway against lymphoma.

By Joe Cantlupe • Oct. 6, 2016

Seattle Genetics on a building, hiring frenzy

The company has grown rapidly and plans to continue doing so, buoyed by a $552 million secondary stock offering in September.

By Joe Cantlupe • Oct. 6, 2016

Merck closes doors at Florida plant

The drugmaker will lay off 112 employees as part of its decision to shutter the Miami Lakes facility. 

By Suzanne Elvidge • Oct. 6, 2016

Cambrex opens new API plant, continuing investment push

Over the past three months, the New Jersey CMO has announced nearly $60 million in manufacturing investments in addition to acquiring PharmaCore, Inc. 

By Suzanne Elvidge • Oct. 6, 2016

Evotec inks deal with C4X Discovery

The drug discovery companies aim to collaboratively develop drugs targeting cancer and autoimmune diseases.

By Joe Cantlupe • Sept. 29, 2016

In cost-cutting move, AstraZeneca closing its PA offices

The U.K. company is shuttering a Pennsylvania plant and relocating jobs to Delaware, where the company intends to maintain its U.S. headquarters. 

By Joe Cantlupe • Sept. 29, 2016

FDA cites Chinese manufacturers for GMP lapses

One firm, Hebei Yuxing, was placed on the regulator's import ban list, which currently includes 54 Chinese suppliers. 

By Ned Pagliarulo • Sept. 29, 2016

Imprimis shuts down Texas plant, axes 8% of jobs

The drug compounder is cutting its staff as it focuses attentions on its New Jersey facility. 

By Suzanne Elvidge • Sept. 29, 2016

Genentech commits $80M upfront in Hanmi licensing deal

The Roche subsidiary will have sole rights to commercialize Hanmi’s tumor-suppressing drug outside of South Korea.

By Jacob Bell • Sept. 29, 2016

Sonoco ThermoSafe buys Laminar Medica

The Illinois-based packing provider will acquire the UK-based pallet shipping producer to strengthen its shipping capabilities for biopharma companies.  

By Joe Cantlupe • Sept. 22, 2016

FDA approval in hand, Sarepta plans for future studies

The Cambridge-based biotech announced plans for a proposed $225 million stock offering to fund further clinical testing on and production of eteplirsen. 

By Ned Pagliarulo • Sept. 22, 2016

GE Healthcare uncorks plans for Irish biopharma park

The medical technology company will invest in a new facility in Cork, Ireland, to help expand bio-manufacturing in the country. 

By Joe Cantlupe • Sept. 22, 2016

Moderna lifts curtain on manufacturing plant plans

With yet another funding round complete, the messenger RNA biotech will invest $110 million to build-out a new plant in Massachusetts. 

By Ned Pagliarulo • Sept. 22, 2016

PCT spears a cancer deal with Adaptimmune

The new agreement expands an existing collaboration between the two companies, and will cover cancer immunotherapy manufacturing. 

By Suzanne Elvidge • Sept. 22, 2016

Momenta, BioFactura team up on biosimilars

With a number of aging, yet still top-selling, biologics nearing patent expiry, biosimilar development in the U.S. is gaining steam. 

By Suzanne Elvidge • Sept. 22, 2016

Horizon opens up cell lines to researchers

A partnership with two high-profile research organizations will allow groups to license access to the cell lines for research into biologics. 

By Lisa LaMotta • Sept. 15, 2016

Lonza builds out gene therapy offerings

A new licensing deal with Mass Eye and Ear will give the Swiss contracting giant access to an AAV vector platform, important for development of new gene therapies. 

By Ned Pagliarulo • Sept. 15, 2016

Novo pulls 71,000 kits of glucagon med from US market

The Danish drugmaker issued the recall of GlucaGen Hypokits after two customer complaints flagged detached needles. 

By Ned Pagliarulo • Sept. 15, 2016